Name | Bryonolic acid |
---|---|
Synonyms |
(2R,4aS,6aS,8aR,10S,12aS,14aS,14bR)-10-Hydroxy-2,4a,6a,9,9,12a,14a-heptamethyl-1,2,3,4,4a,5,6,6a,7,8,8a,9,10,11,12,12a,13,14,14a,14b-icosahydro-2-picenecarboxylic acid
(2S,4aS,6aS,8aR,10S,12aS,14aS,14bR)-10-Hydroxy-2,4a,6a,9,9,12a,14a-heptamethyl-1,2,3,4,4a,5,6,6a,7,8,8a,9,10,11,12,12a,13,14,14a,14b-icosahydropicene-2-carboxylic acid (2S,4aS,6aS,8aR,10S,12aS,14aS,14bR)-10-Hydroxy-2,4a,6a,9,9,12a,14a-heptamethyl-1,2,3,4,4a,5,6,6a,7,8,8a,9,10,11,12,12a,13,14,14a,14b-icosahydro-2-picenecarboxylic acid 2-Picenecarboxylic acid, 1,2,3,4,4a,5,6,6a,7,8,8a,9,10,11,12,12a,13,14,14a,14b-eicosahydro-10-hydroxy-2,4a,6a,9,9,12a,14a-heptamethyl-, (2R,4aS,6aS,8aR,10S,12aS,14aS,14bR)- 2-Picenecarboxylic acid, 1,2,3,4,4a,5,6,6a,7,8,8a,9,10,11,12,12a,13,14,14a,14b-eicosahydro-10-hydroxy-2,4a,6a,9,9,12a,14a-heptamethyl-, (2S,4aS,6aS,8aR,10S,12aS,14aS,14bR)- |
Description | Bryonolic acid is an active triterpenoid compound with immunomodulatory, anti-inflammatory, antioxidant and anticancer activities[1][2][3]. |
---|---|
Related Catalog | |
In Vitro | Bryonolic acid exerts anti-allergic activity by inhibiting homologous passive cutaneous anaphylaxis and delayed hypersensitivity. Bryonolic acid reduces nitric oxide by suppressing inducible nitric oxide synthase expression, indicating anti-inflammatory activity[1]. In rat adrenal pheochromocytoma (PC12) cells, Bryonolic acid against N-methyl-D-aspartate (NMDA)-induced neurotoxicity, indicating it as a candidate neuroprotective agent for cerebral ischemic treatment[1]. Bryonolic acid (1-200 μM) inhibits acyl-coA: cholesterol acyl transferase (ACAT) activity in rat liver microsomes in a concentration-dependent manner, blocking the biosynthesis of the cholesterol fatty acid ester tumour promoter. Bryonolic acid inhibits ACAT in intact cancer cells with an IC50 of 12.6 µM[2]. Bryonolic acid inhibits both clonogenicity and invasiveness in MCF-7 MB-231, U87 and 3T3-EA cells[2]. |
In Vivo | Bryonolic acid (500 mg/kg; i.p.; once) potently induces HO-1 in a manner dependent on the Nrf2-Keap1 pathway[3]. Animal Model: Wild-type and Nrf2-/- mice[3] Dosage: 500 mg/kg Administration: i.p.; once Result: Induced HO-1 in a manner dependent on the Nrf2-Keap1 pathway. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 553.3±50.0 °C at 760 mmHg |
Molecular Formula | C30H48O3 |
Molecular Weight | 456.700 |
Flash Point | 302.5±26.6 °C |
Exact Mass | 456.360352 |
PSA | 57.53000 |
LogP | 8.99 |
Vapour Pressure | 0.0±3.4 mmHg at 25°C |
Index of Refraction | 1.557 |
Hazard Codes | Xi |
---|